The website biologenkompass.de published a story about our Business Development Manager Roland Stieger (in German). The interview was done by Ulrike Herzog, who is one of the founders of biologenkompass.de. The goal of her team is to inform biologists with potential...

  Staburo took part in the 2016 BIO Europe Conference in Cologne between 7 and 9 November. The conference featured a wide range of interesting topics for statisticians in the pharmaceutical and healthcare industry, including health technology assessment,...

The incorporation of biomarkers into drug development becomes more and more important, as they provide essential information to find the right therapy at the right time for the right patient (“precision medicine”). This talk provided an overview on the roles of...

On 13 October 2016, managing directors and press officers of biotech, pharmaceutical and venture capital companies, as well as journalists, were meeting at the Faculty Club G2B of the IZB in Martinsried near Munich. There were three compact presentations held before a...

We are very glad to welcome Vicky Stahl and Maximilian Siebold back in our team. Vicky and Max already worked as student interns at Staburo earlier and will support our clients in the area of statistical programming. We are very happy to have you back in the team!...

The statistical principles of equivalence trials and non-inferiority, as well as the special case bioequivalence, were presented. From a statistical perspective, being non-inferior or bioequivalent means to be only irrelevantly inferior or different, respectively....

We are very happy to welcome Julia Breitenbruch in our team. Julia will support our clients with her experience in the areas of statistical programming and biostatistics. We are looking forward to a great cooperation!  

Multiple Imputation (MI) is a technique to replace missing data with substituted values. The promise of this method is to estimate less biased estimates compared to state-of-the-art methods like Last Observation Carried Forward (LOCF). In a MI approach, the same...

In the past few years, more and more articles dealing with Bayesian statistics and Bayesian designs in clinical trials were published. Such designs are being developed especially for clinical trials with small number of patients, where it is crucial to get the most...